Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: The milk-derived fusion peptide, ACFP, suppresses the growth of primary human ovarian cancer cells by regulating apoptotic gene expression and signaling pathways

Fig. 6

Real-time PCR validates ACFP-induced changes in bcl-xl, bax, akt, caspase-3, CDC25C and cyclinB1 mRNA levels in primary human ovarian cancer cells. a After ACFP treatment at different concentrations for 48 h, RNA was harvested from primary human ovarian cancer cells; real-time PCR using primers specific to bcl-xl, bax, akt, caspase-3, CDC25C and cyclinB1 was performed. b After 5 × 10−3 g/L ACFP treatment for different time, mRNA expressions of bcl-xl, bax, akt, caspase-3, CDC25C and cyclinB1 were detected in human primary ovarian cancer cells. The data in a and b are shown as means ± SD of 12 primary ovarian cancer cells measurements from 12 patients, * P < 0.05, ** P < 0.01 compared with control (the vehicle group), taken β-actin as reference gene

Back to article page